ibuprofen has been researched along with Coronary Disease in 26 studies
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In parallel with experimental research into methods for salvage of ischemic myocardium after acute myocardial infarction (AMI) over the last decade, there has been a growing interest in prostaglandins (PG) and their inhibition by aspirin-like drugs or nonsteroidal anti-inflammatory drugs (NSAID)." | 4.76 | Prostaglandin inhibition and myocardial infarct size. ( Becker, LC; Jugdutt, BI, 1981) |
| "To estimate the net cardiovascular (CV) (coronary heart disease, stroke, congestive heart failure), and gastrointestinal (GI) (peptic ulcer complications) risk-benefit public health impact of the use of celecoxib compared to non-selective NSAIDs in the arthritis population." | 3.74 | Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level. ( Castellsague, J; Maguire, A; Perez-Gutthann, S; Varas-Lorenzo, C, 2007) |
| "Non-aspirin, non-steroidal anti-inflammatory drugs (NANSAIDs) have complex effects that could either prevent or promote coronary heart disease." | 3.71 | Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. ( Daugherty, JR; Griffin, MR; Hall, K; Ray, WA; Stein, CM, 2002) |
| "Arrhythmias were produced by ouabain (2." | 3.67 | Prostaglandin involvement in hypersensitivity of ischemic hearts to arrhythmogenic influence of ouabain. ( Ferrier, GR; Karmazyn, M; Moffat, MP, 1985) |
| "Naproxen was associated with an OR of 0." | 1.32 | Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. ( García Rodríguez, LA; González-Pérez, A; Maguire, A; Varas-Lorenzo, C, 2004) |
| "Necrosis was minimal, averaging only 2." | 1.27 | Impaired function of salvaged myocardium: two-dimensional echocardiographic quantification of regional wall thickening in the open-chest dog. ( Becker, LC; Blumenthal, DS; Bulkley, BH; Hutchins, GM; Weisfeldt, ML; Weiss, JL, 1983) |
| "Ibuprofen was the most effective, producing an average recovery of 70% (P less than 0." | 1.27 | Contribution of prostaglandins to reperfusion-induced ventricular failure in isolated rat hearts. ( Karmazyn, M, 1986) |
| "Adenosine was extracted at rest, but during ischemia there was a significant release of its metabolite hypoxanthine, indicating increased myocardial breakdown of high-energy adenine nucleotides." | 1.27 | Coronary flow regulation in patients with ischemic heart disease: release of purines and prostacyclin and the effect of inhibitors of prostaglandin formation. ( Berglund, B; Edlund, A; Kaijser, L; Nowak, J; Patrono, C; Sollevi, A; van Dorne, D; Wennmalm, A, 1985) |
| "In 67 dogs with a 60-80% coronary stenosis produced by an external constricting plastic ring, blood flow measured with an electromagnetic flowmeter showed cyclical flow reductions of varying magnitude and duration, and then an abrupt return to control flow." | 1.26 | Blood flow reductions in stenosed canine coronary arteries: vasospasm or platelet aggregation? ( Folts, JD; Gallagher, K; Rowe, GG, 1982) |
| "Flurbiprofen was given at 0." | 1.26 | Effects of flurbiprofen on myocardial cell damage in acute myocardial ischemia. ( Carrow, BA; Lefer, AM; Smith, EF, 1980) |
| "Ibuprofen was administered intravenously at a dose of 12." | 1.26 | Beneficial effects of ibuprofen in acute myocardial ischemia. ( Lefer, AM; Polansky, EW, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (73.08) | 18.7374 |
| 1990's | 1 (3.85) | 18.2507 |
| 2000's | 5 (19.23) | 29.6817 |
| 2010's | 1 (3.85) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhala, N | 1 |
| Emberson, J | 1 |
| Merhi, A | 1 |
| Abramson, S | 1 |
| Arber, N | 1 |
| Baron, JA | 1 |
| Bombardier, C | 1 |
| Cannon, C | 1 |
| Farkouh, ME | 1 |
| FitzGerald, GA | 1 |
| Goss, P | 1 |
| Halls, H | 1 |
| Hawk, E | 1 |
| Hawkey, C | 1 |
| Hennekens, C | 1 |
| Hochberg, M | 1 |
| Holland, LE | 1 |
| Kearney, PM | 1 |
| Laine, L | 1 |
| Lanas, A | 1 |
| Lance, P | 1 |
| Laupacis, A | 1 |
| Oates, J | 1 |
| Patrono, C | 2 |
| Schnitzer, TJ | 1 |
| Solomon, S | 1 |
| Tugwell, P | 1 |
| Wilson, K | 1 |
| Wittes, J | 1 |
| Baigent, C | 1 |
| Ray, WA | 2 |
| Stein, CM | 2 |
| Daugherty, JR | 2 |
| Hall, K | 2 |
| Arbogast, PG | 1 |
| Griffin, MR | 2 |
| García Rodríguez, LA | 1 |
| Varas-Lorenzo, C | 2 |
| Maguire, A | 2 |
| González-Pérez, A | 1 |
| Castellsague, J | 1 |
| Perez-Gutthann, S | 1 |
| Marijon, E | 1 |
| Fressonnet, R | 1 |
| Haggui, A | 1 |
| Mousseaux, E | 1 |
| Redheuil, A | 1 |
| Aiken, JW | 1 |
| Shebuski, RJ | 1 |
| Miller, OV | 1 |
| Gorman, RR | 1 |
| Blumenthal, DS | 1 |
| Becker, LC | 4 |
| Bulkley, BH | 3 |
| Hutchins, GM | 3 |
| Weisfeldt, ML | 1 |
| Weiss, JL | 1 |
| Jugdutt, BI | 2 |
| Folts, JD | 1 |
| Gallagher, K | 1 |
| Rowe, GG | 1 |
| Kirlin, PC | 1 |
| Romson, JL | 3 |
| Pitt, B | 1 |
| Abrams, GD | 1 |
| Schork, MA | 1 |
| Lucchesi, BR | 4 |
| Darsee, JR | 1 |
| Kloner, RA | 1 |
| Smith, EF | 1 |
| Carrow, BA | 1 |
| Lefer, AM | 2 |
| Haack, DW | 2 |
| Bush, LR | 1 |
| Chen, CY | 1 |
| Chen, CS | 1 |
| Polansky, EW | 1 |
| Karmazyn, M | 2 |
| Crawford, MH | 1 |
| Grover, FL | 1 |
| Kolb, WP | 1 |
| McMahan, CA | 1 |
| O'Rourke, RA | 1 |
| McManus, LM | 1 |
| Pinckard, RN | 1 |
| Michael, LH | 1 |
| Hunt, JR | 1 |
| Lewis, RM | 1 |
| Entman, ML | 1 |
| Reimer, KA | 1 |
| Jennings, RB | 1 |
| Cobb, FR | 1 |
| Murdock, RH | 1 |
| Greenfield, JC | 1 |
| Schwartz, RP | 1 |
| Bailey, KR | 1 |
| Edlund, A | 1 |
| Berglund, B | 1 |
| van Dorne, D | 1 |
| Kaijser, L | 1 |
| Nowak, J | 1 |
| Sollevi, A | 1 |
| Wennmalm, A | 1 |
| Moffat, MP | 1 |
| Ferrier, GR | 1 |
| Werns, SW | 1 |
| Shea, MJ | 1 |
| Grover, GJ | 1 |
| Weiss, HR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| Astaxanthin Effects on Osteoarthritis Associated Pain and Inflammatory Indicators[NCT03664466] | 0 participants (Actual) | Interventional | 2021-04-29 | Withdrawn (stopped due to Inadequate funding) | |||
| Analgesic Efficacy of Preoperative Oral Administration of Dexketoprofen Trometamol in Third Molar Surgery, Compared to Postoperative Administration[NCT02380001] | Phase 4 | 60 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Treatment Efficacy of 'Shinbaro Capsule' in the Treatment of Hand Osteoarthritis: Randomized, Double-blinded, Placebo-controlled, Multicenter Investigator Initiated Trial.[NCT01910116] | Phase 2/Phase 3 | 220 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Effects on Omission of NSAIDs on the Consumption of Opioids in the Standard Analgesic Regimen After Elective Laparoscopic Colorectal Cancer Resection in an ERAS Setting. A Retrospective Single-center Cohort Study.[NCT04448652] | 502 participants (Actual) | Observational [Patient Registry] | 2015-01-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Change in AUSCAN function score at 12 weeks from baseline = Function score at 12 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -11 |
| Placebo | -2.9 |
"Change in AUSCAN function score at 16 weeks from baseline = Function score at 16 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.9 |
| Placebo | -4.8 |
"Change in AUSCAN function score at 4 weeks from baseline = Function score at 4 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Basline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -6.8 |
| Placebo | -3.7 |
"Change in AUSCAN function score at 8 weeks from baseline = Function score at 8 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.7 |
| Placebo | -4.8 |
"Change in AUSCAN pain score at 4 weeks from baseline = Pain at 4 weeks (0-100) - Pain at baseline (0-100).~AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.0 |
| Placebo | -2.2 |
"Change in AUSCAN pain score at 12 weeks from baseline = Pain at 12 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -14.6 |
| Placebo | -8.0 |
"Change in AUSCAN pain score at 16 weeks from baseline = Pain at 16 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -15.6 |
| Placebo | -4.4 |
"Change in AUSCAN pain score at 8 weeks from baseline = Pain at 8 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -13.4 |
| Placebo | -2.2 |
"Change in AUSCAN stiffness score at 12 weeks from baseline = Stiffness at 12 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Basline and 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -14.0 |
| Placebo | -11.0 |
"Change in AUSCAN stiffness score at 16 weeks from baseline = Stiffness at 16 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline, 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -10.0 |
| Placebo | -8.0 |
"Change in AUSCAN stiffness score at 4 weeks from baseline = Stiffness at 4 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.0 |
| Placebo | -6.0 |
"Change in AUSCAN stiffness score at 8 weeks from baseline = Stiffness at 8 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: baseline and 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -12.0 |
| Placebo | -6 |
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baselie and 16 weeks
| Intervention | participants (Number) |
|---|---|
| Shinbaro | 55 |
| Placebo | 40 |
"Change in Patient global assessment (PGA) at 12 weeks from baseline = PGA at 12 weeks (0-100)- PGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -11.0 |
| Placebo | -6.0 |
"Change in Patient global assessment (PGA) at 16 weeks from baseline = PGA at 16 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -10.0 |
| Placebo | -8.5 |
"Change in Patient global assessment (PGA) at 4 weeks from baseline = PGA at 4 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.0 |
| Placebo | -3.0 |
"Change in Patient global assessment (PGA) at 8 weeks from baseline = PGA at 8 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -10.0 |
| Placebo | -6.0 |
"Change in Physician global assessment (PhGA) at 12 weeks from baseline = PhGA at 12 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -19.0 |
| Placebo | -13 |
"Change in Physician global assessment (PhGA) at 16 weeks from baseline = PhGA at 16 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -12 |
| Placebo | -6.5 |
"Change in Physician global assessment (PhGA) at 4 weeks from baseline = PhGA at 4 weeks (0-100)- PhGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: baseline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -12 |
| Placebo | -7.0 |
"Change in Physician global assessment (PhGA) at 8 weeks from baseline = PhGA at 8 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -16.0 |
| Placebo | -11.5 |
"Change in Swollen joint count (SJC) at 12 weeks from baseline = SJC at 12 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | 0 |
| Placebo | 0 |
"Change in Swollen joint count (SJC) at 16 weeks from baseline = SJC at 16 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | 0 |
| Placebo | 0 |
"Change in Swollen joint count (SJC) at 4 weeks from baseline = SJC at 4 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | 0 |
| Placebo | 0 |
"Change in Swollen joint count (SJC) at 8 weeks from baseline = SJC at 8 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | 0 |
| Placebo | 0 |
"Change in Tender joint count (TJC) at 12 weeks from baseline = TJC at 12 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | joints (Median) |
|---|---|
| Shinbaro | -2.0 |
| Placebo | -1.0 |
"Change in Tender joint count (TJC) at 16 weeks from baseline = TJC at 16 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | joints (Median) |
|---|---|
| Shinbaro | -2.0 |
| Placebo | -1.0 |
"Change in Tender joint count (TJC) at 4 weeks from baseline = TJC at 4 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | joints (Median) |
|---|---|
| Shinbaro | -1 |
| Placebo | 0 |
"Change in Tender joint count (TJC) at 8 weeks from baseline = TJC at 8 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | -1.0 |
| Placebo | -1.0 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: 12 weeks and 16 weeks
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| Placebo | 2 | 104 |
| Shinbaro | 4 | 105 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: 4 weeks and 8 weeks
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| Placebo | 7 | 99 |
| Shinbaro | 10 | 99 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: 8 weeks and 12 weeks
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| Placebo | 4 | 102 |
| Shinbaro | 4 | 105 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: Baseline 4 weeks
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| Placebo | 4 | 102 |
| Shinbaro | 7 | 102 |
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | participants (Number) | |
|---|---|---|
| responder | nonresponder | |
| Placebo | 43 | 63 |
| Shinbaro | 62 | 47 |
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | participants (Number) | |
|---|---|---|
| responder | nonresponder | |
| Placebo | 38 | 68 |
| Shinbaro | 56 | 53 |
Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | participants (Number) | |
|---|---|---|
| Responder | Nonresponder | |
| Placebo | 32 | 74 |
| Shinbaro | 48 | 61 |
2 reviews available for ibuprofen and Coronary Disease
| Article | Year |
|---|---|
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Prostaglandin inhibition and myocardial infarct size.
Topics: Acute Disease; Animals; Aspirin; Coronary Disease; Humans; Ibuprofen; Indomethacin; Models, Biologic | 1981 |
24 other studies available for ibuprofen and Coronary Disease
| Article | Year |
|---|---|
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Coronary Disease; Cyclo | 2002 |
Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiotonic Agents; Case- | 2004 |
Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular D | 2007 |
Spontaneous coronary dissection of the left main stem after intense physical activity--regression under conservative strategy.
Topics: Angioplasty, Balloon, Coronary; Coronary Disease; Cyclooxygenase Inhibitors; Drug-Eluting Stents; Ec | 2008 |
Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis.
Topics: Acrylates; Animals; Aspirin; Blood Platelets; Coronary Disease; Cyclic AMP; Cyclooxygenase Inhibitor | 1981 |
Impaired function of salvaged myocardium: two-dimensional echocardiographic quantification of regional wall thickening in the open-chest dog.
Topics: Animals; Coronary Circulation; Coronary Disease; Dipyridamole; Dogs; Echocardiography; Epoprostenol; | 1983 |
Blood flow reductions in stenosed canine coronary arteries: vasospasm or platelet aggregation?
Topics: Animals; Aspirin; Constriction, Pathologic; Coronary Angiography; Coronary Circulation; Coronary Dis | 1982 |
Ibuprofen-mediated infarct size reduction: effects on regional myocardial function in canine myocardial infarction in canine myocardial infarction.
Topics: Animals; Arterial Occlusive Diseases; Blood Pressure; Coronary Disease; Dogs; Heart Rate; Ibuprofen; | 1982 |
Dependency of location of salvageable myocardium on type of intervention.
Topics: Animals; Coronary Circulation; Coronary Disease; Dogs; Female; Flurbiprofen; Glycine; Heart; Ibuprof | 1981 |
Salvage of ischemic myocardium by ibuprofen during infarction in the conscious dog.
Topics: Animals; Blood Pressure; Coronary Circulation; Coronary Disease; Dogs; Electrocardiography; Heart Ra | 1980 |
Effects of flurbiprofen on myocardial cell damage in acute myocardial ischemia.
Topics: Acute Disease; Animals; Blood Pressure; Cats; Cell Membrane; Coronary Disease; Creatine Kinase; Elec | 1980 |
Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of anti-thrombotic agents.
Topics: Animals; Anticoagulants; Collagen; Coronary Disease; Coronary Vessels; Disease Models, Animal; Dogs; | 1980 |
The beneficial effects of oral ibuprofen on coronary artery thrombosis and myocardial ischemia in the conscious dog.
Topics: Administration, Oral; Animals; Arteries; Coronary Disease; Coronary Vessels; Dogs; Drug Evaluation; | 1980 |
Stereoselective disposition of ibuprofen in patients with compromised renal haemodynamics.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Coronary Disease; Diabetes Mellitus; Female; Heart Fa | 1995 |
Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study.
Topics: Age Distribution; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bias; C | 2002 |
Beneficial effects of ibuprofen in acute myocardial ischemia.
Topics: Acute Disease; Animals; Cathepsins; Cats; Coronary Disease; Creatine Kinase; Drug Evaluation, Precli | 1979 |
Contribution of prostaglandins to reperfusion-induced ventricular failure in isolated rat hearts.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Coronary Circulation; Coronary Disease; Cyclooxygena | 1986 |
Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury.
Topics: Animals; Complement Activation; Complement System Proteins; Coronary Disease; Creatine Kinase; Elapi | 1988 |
Myocardial ischemia: platelet and thromboxane concentrations in cardiac lymph and the effects of ibuprofen and prostacyclin.
Topics: Animals; Blood Platelets; Coronary Disease; Dogs; Epoprostenol; Ibuprofen; Lymph; Platelet Aggregati | 1986 |
Animal models for protecting ischemic myocardium: results of the NHLBI Cooperative Study. Comparison of unconscious and conscious dog models.
Topics: Anesthesia; Animal Testing Alternatives; Animals; Arterial Occlusive Diseases; Coronary Circulation; | 1985 |
Coronary flow regulation in patients with ischemic heart disease: release of purines and prostacyclin and the effect of inhibitors of prostaglandin formation.
Topics: Adenosine; Adult; Aged; Coronary Circulation; Coronary Disease; Epoprostenol; Humans; Ibuprofen; Ind | 1985 |
Prostaglandin involvement in hypersensitivity of ischemic hearts to arrhythmogenic influence of ouabain.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Arachidonic Acid; Arachidonic Acids; Arrhythmias, Cardiac; As | 1985 |
Free radicals in ischemic myocardial injury.
Topics: Animals; Arachidonate Lipoxygenases; Catalase; Coronary Disease; Dogs; Free Radicals; Ibuprofen; Inf | 1985 |
Effect of ibuprofen and indomethacin on the O2 supply/consumption balance in ischemic rabbit myocardium.
Topics: Animals; Anti-Inflammatory Agents; Coronary Circulation; Coronary Disease; Heart; Ibuprofen; Indomet | 1985 |